News tracker · Cited to primary sources
FDA peptide status 2026: the July PCAC vote tracker
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews 7 peptides — including BPC-157 and TB-500 — to decide whether they can be legally compounded. As of July 6, 2026, the vote is pending. This page updates the moment the ruling lands.
Vote results — updates after July 24, 2026
The committee had not voted as of July 6, 2026. When it does, each compound's recommendation (eligible for 503A compounding, or not) will appear in the table below and in this box. Subscribe to get the outcome the day it's published.
What is PCAC and why does it matter?
PCAC — the Pharmacy Compounding Advisory Committee — is the expert panel that advises the FDA on which bulk substances pharmacies may legally compound under Section 503A. Its vote is a recommendation, not a final rule: the FDA usually follows it but decides on its own. For peptides, this committee is effectively the gatekeeper between “you can get this from a licensed pharmacy” and “gray market only.”
Which peptides is the FDA reviewing in July 2026?
7 peptides are on the July 23–24 docket. Six are reviewed on the first day and the nootropic/longevity compounds on the second. Here is each one with the evidence grade we assigned it and its status heading into the vote:
| Peptide | Evidence grade | Status entering vote | Vote outcome |
|---|---|---|---|
| Semax | C | Under FDA review (503A) | Pending |
| BPC-157 | D | Under FDA review (503A) | Pending |
| TB-500 | D | Under FDA review (503A) | Pending |
| KPV | D | Under FDA review (503A) | Pending |
| MOTS-c | D | Under FDA review (503A) | Pending |
| Epitalon | D | Under FDA review (503A) | Pending |
| DSIP (nominated as Emideltide) | — | Under FDA review (503A) · profile forthcoming | Pending |
Note that a high grade and a favorable vote are different things. Most of these compounds are Grade D — animal studies only — so a “yes” would make them legally compoundable, not proven to work. See how each grade is assigned on how we grade evidence.
How did we get here?
In April 2026 the FDA published a reclassification (Federal Register docket FDA-2025-N-6895) that removed a group of peptides from the 503A Category 2 bulk-substances list, moving them into limbo pending review. That reclassification — and the political attention around peptides in 2026 — is what put these seven compounds in front of PCAC this July. Until the committee acts, any clinic openly selling the removed peptides is a compliance red flag, not a legal source.
What happens if PCAC votes yes — or no?
If the vote is favorable
The peptide becomes eligible for 503A compounding, opening a legal, supervised route through licensed pharmacies and telehealth. It does notmean the peptide is FDA-approved or proven effective — the evidence grade doesn't change, only the access route.
If the vote is unfavorable
No legal compounded route exists. Clinics cannot lawfully prescribe it, and it stays gray-market only — the current fate of CJC-1295 (nomination withdrawn) and thymosin alpha-1 (voted down in 2024). Our access sections stay empty for those compounds.
When is the next FDA peptide decision?
A second PCAC meeting is scheduled before February 2027 to review additional peptides removed from Category 2 in April 2026 — reported to include injectable GHK-Cu, Melanotan-2, LL-37, Selank, and Ipamorelin. We'll add each to this tracker as the meeting is confirmed. For the legal framework behind all of this, see are peptides legal?